PEPGEN INC (PEPG)
US7133171055 - Common Stock
Let's take a look at the stocks that are in motion in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
Which stocks are gapping on Monday?
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
PepGen to Participate in Upcoming Investor Conferences
RSI Alert: PepGen (PEPG) Now Oversold
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
Oversold Conditions For PepGen (PEPG)
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
PEPG Stock Earnings: PepGen Misses EPS for Q2 2024
PEPG stock results show that PepGen missed analyst estimates for earnings per share the second quarter of 2024.
PEPG Stock Earnings: PepGen Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PepGen (NASDAQ:PEPG) just reported results for the second quarter of 2024.PepGe...
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
PEPG Investors Have Opportunity to Join PepGen Inc. Securities Fraud Investigation with the Schall Law Firm
PepGen Announces Executive Team Promotions
PEPG Stock Earnings: PepGen Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PepGen (NASDAQ:PEPG) just reported results for the first quarter of 2024.PepGen...
PEPG Stock Earnings: PepGen Beats EPS for Q1 2024
PEPG stock results show that PepGen beat analyst estimates for earnings per share the first quarter of 2024.
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
– CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose...
PepGen to Participate in Upcoming Investor Conferences
PepGen to Participate in Upcoming Investor Conferences
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
PEPG stock results show that PepGen beat analyst estimates for earnings per share the fourth quarter of 2023.
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PepGen (NASDAQ:PEPG) just reported results for the fourth quarter of 2023.PepGe...
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary...